Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
5